Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.CALC · Entity 7804 | Director · CHIEF EXECUTIVE OFFICER | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2036-09-23 | Direct | 360,000 |
Reported balance
After 2026-09-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-24 · Grant · Acquired 360,000 · Balance 360,000 F1: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:24 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001484729-26-000006 · form4-09282026_080938.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2036-09-23 F1 · derivative.exercise_date: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:35 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 186,729 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001484729-26-000005 · form4-08212026_100832.xml · derivative · entry 2 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,729 Underlying: Common Stock · 186,729 shares Expires 2031-06-25 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. F3 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:35 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 186,729 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001484729-26-000005 · form4-08212026_100832.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,729 Underlying: Common Stock · 186,729 shares Expires 2027-12-25 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 12:45 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 186,729 | $0.80 | $149,999.41 |
DisclosureSEC source: 0001484729-26-000004 · form4-06292026_080601.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,655 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| July 21, 2025 Filed Jul 21, 2025 18:02 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $3.40 | $3,400.00 |
DisclosureSEC source: 0001415889-25-020052 · form4-07212025_060739.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Scheibler-Leheny Family Living Trust Disclosed balance after: 3,500 Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 01:29 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,500 | $2.47 | $6,175.00 |
DisclosureSEC source: 0001415889-25-019816 · form4-07162025_010710.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Scheibler-Leheny Family Living Trust Disclosed balance after: 2,500 Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:26 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77,625 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018305 · form4-06262025_100619.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,625 Underlying: Common Stock · 77,625 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 20:30 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 285,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-011358 · form4-04252025_080419.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires 2035-04-22 F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period. Read SEC document |
| April 05, 2025 Filed Apr 8, 2026 01:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 148,482 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001484729-26-000002 · form4-04072026_090402.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,482 Underlying: Common Stock · 148,482 shares Expires 2036-04-04 F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 17:25 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 20,000 | $3.75 | $75,000.00 |
DisclosureSEC source: 0001415889-24-025880 · form4-11012024_051148.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,926 Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 23:44 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $4.19 | $4,189.80 |
DisclosureSEC source: 0001415889-24-022361 · form4-08272024_110843.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,926 F1 · price: The weighted average purchase price for the transaction reported was $4.1898, and the range of prices were between $4.20 and $4.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:07 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022500 · form4-08282024_110856.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:33 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011343 · form4-04232024_010439.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 01:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 45,543 | $0.13 Strike: $7.15 | $5,692.88 |
DisclosureSEC source: 0001415889-24-001828 · form4-01252024_080101.xml · derivative · entry 7 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,543 Underlying: Common Stock · 45,543 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F4 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F4 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 01:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 45,543 | $0.13 Strike: $5.36 | $5,692.88 |
DisclosureSEC source: 0001415889-24-001828 · form4-01252024_080101.xml · derivative · entry 6 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,543 Underlying: Common Stock · 45,543 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 01:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 91,086 | $4.27 | $388,618.42 |
DisclosureSEC source: 0001415889-24-001828 · form4-01252024_080101.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,926 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 01:42 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $3.34 | $6,680.00 |
DisclosureSEC source: 0001209191-23-054770 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,840 F1 · price: The weighted average purchase price for the transaction reported was $3.34, and the range of prices were between $3.30 and $3.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 23:09 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,440 | $3.12 | $7,614.75 |
DisclosureSEC source: 0001209191-23-054633 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,840 F1 · price: The weighted average purchase price for the transaction reported was $3.1208, and the range of prices were between $3.11 and $3.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:39 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 5,000 | $2.85 | $14,250.00 |
DisclosureSEC source: 0001209191-23-054577 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,400 Read SEC document |
| June 09, 2023 Filed Jun 10, 2023 01:16 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 400 | $5.25 | $2,100.00 |
DisclosureSEC source: 0001209191-23-036127 · doc4.xml · nonDerivative · entry 2 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,328 Read SEC document |
| June 08, 2023 Filed Jun 10, 2023 01:16 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 928 | $5.23 | $4,850.56 |
DisclosureSEC source: 0001209191-23-036127 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,928 F1 · price: The weighted average purchase price for the transaction reported was $5.2269, and the range of prices were between $5.20 and $5.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 08, 2023 Filed Jun 15, 2023 23:51 UTC Amendment | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $5.23 | $5,225.00 |
DisclosureSEC source: 0001209191-23-037586 · doc4a.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 F1 · price: The weighted average purchase price for the transaction reported was $5.225, and the range of prices were between $5.20 and $5.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 01:09 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $5.25 | $5,247.80 |
DisclosureSEC source: 0001209191-23-035609 · doc4.xml · nonDerivative · entry 2 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 F2 · price: The weighted average purchase price for the transaction reported was $5.2478, and the range of prices were between $5.225 and $5.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:09 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $5.13 | $5,128.70 |
DisclosureSEC source: 0001209191-23-035609 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 F1 · price: The weighted average purchase price for the transaction reported was $5.1287, and the range of prices were between $4.48 and $5.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 23:25 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $4.80 | $4,800.00 |
DisclosureSEC source: 0001209191-23-034646 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 23:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $4.21 | $4,210.00 |
DisclosureSEC source: 0001209191-23-033461 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · price: The weighted average purchase price for the transaction reported was $4.21, and the range of prices were between $4.00 and $4.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 23, 2023 Filed May 25, 2023 00:15 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 3,000 | $3.34 | $10,031.70 |
DisclosureSEC source: 0001209191-23-032024 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 F1 · price: The weighted average purchase price for the transaction reported was $3.3439, and the range of prices were between $3.09 and $3.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 16, 2023 Filed May 18, 2023 22:03 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $2.69 | $2,690.00 |
DisclosureSEC source: 0001209191-23-030778 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| May 16, 2023 Filed Jun 5, 2023 23:23 UTC Amendment | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $2.70 | $2,698.00 |
DisclosureSEC source: 0001209191-23-034642 · doc4a.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,000 F1 · price: The weighted average purchase price for the transaction reported was $2.698, and the range of prices were between $2.68 and $2.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 08, 2023 Filed May 10, 2023 22:16 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,380 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-23-028546 · doc4.xml · derivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,380 Underlying: Common Stock · 110,380 shares Expires 2033-05-07 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 9,935 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 17 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV V, LLC Disclosed balance after: 9,935 Underlying: Common Stock · 9,935 shares Expires 2026-05-25 F22 · price: Received in exchange for a stock option to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement. F13 · derivative.exercise_date: Immediately exercisable. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 9,935 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 16 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV V, LLC Disclosed balance after: 9,935 Underlying: Common Stock · 9,935 shares Expires 2026-02-22 F22 · price: Received in exchange for a stock option to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement. F13 · derivative.exercise_date: Immediately exercisable. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 12,342 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 15 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,342 Underlying: Common Stock · 12,342 shares Expires 2023-03-19 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F21 · price: Received in exchange for a stock option to acquire 428,566 shares of common stock of CalciMedica pursuant to the Merger Agreement. F18 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 30,443 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 14 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,443 Underlying: Common Stock · 30,443 shares Expires 2033-03-19 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F20 · price: Received in exchange for a stock option to acquire 1,057,071 shares of common stock of CalciMedica pursuant to the Merger Agreement. F18 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 1,717 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 13 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,717 Underlying: Common Stock · 1,717 shares Expires 2033-03-19 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F19 · price: Received in exchange for a stock option to acquire 59,641 shares of common stock of CalciMedica pursuant to the Merger Agreement. F18 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 1,062 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 12 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,062 Underlying: Common Stock · 1,062 shares Expires 2032-08-30 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F17 · price: Received in exchange for a stock option to acquire 36,905 shares of common stock of CalciMedica pursuant to the Merger Agreement. F13 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 2,030 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 11 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,030 Underlying: Common Stock · 2,030 shares Expires 2032-08-30 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F16 · price: Received in exchange for a stock option to acquire 70,490 shares of common stock of CalciMedica pursuant to the Merger Agreement. F13 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 3,552 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 10 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,552 Underlying: Common Stock · 3,552 shares Expires 2032-08-30 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F15 · price: Received in exchange for a stock option to acquire 123,357 shares of common stock of CalciMedica pursuant to the Merger Agreement. F13 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 13,964 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 9 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,964 Underlying: Common Stock · 13,964 shares Expires 2031-06-30 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F12 · price: Received in exchange for a stock option to acquire 484,863 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 19,826 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 8 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,826 Underlying: Common Stock · 19,826 shares Expires 2031-04-27 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F14 · price: Received in exchange for a stock option to acquire 688,404 shares of common stock of CalciMedica pursuant to the Merger Agreement. F13 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 13,964 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 7 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,964 Underlying: Common Stock · 13,964 shares Expires 2031-04-27 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F12 · price: Received in exchange for a stock option to acquire 484,863 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 30,381 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 6 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,381 Underlying: Common Stock · 30,381 shares Expires 2030-06-29 F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F10 · price: Received in exchange for a stock option to acquire 1,054,921 shares of common stock of CalciMedica pursuant to the Merger Agreement. F8 · derivative.exercise_date: 25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 76,173 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 5 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,173 Underlying: Common Stock · 76,173 shares Expires 2030-01-23 F7 · price: Received in exchange for a stock option to acquire 2,644,900 shares of common stock of CalciMedica pursuant to the Merger Agreement. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 11,232 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 4 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,232 Underlying: Common Stock · 11,232 shares Expires 2029-04-24 F6 · price: Received in exchange for a stock option to acquire 390,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 316,109 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · nonDerivative · entry 3 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV VI, LLC Disclosed balance after: 316,109 F4 · price: Received in exchange for 10,975,977 shares of the common stock of CalciMedica pursuant to the Merger Agreement. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 66,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · nonDerivative · entry 2 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV V, LLC Disclosed balance after: 66,228 F3 · price: Received in exchange for 2,299,564 shares of the common stock of CalciMedica pursuant to the Merger Agreement. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:47 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 356,989 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020676 · doc4.xml · nonDerivative · entry 1 Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Valence Investments SPV IV, LLC Disclosed balance after: 356,989 F1 · price: Received in exchange for an aggregate of 12,395,423 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.